JP2026004397A5 - - Google Patents
Info
- Publication number
- JP2026004397A5 JP2026004397A5 JP2025161356A JP2025161356A JP2026004397A5 JP 2026004397 A5 JP2026004397 A5 JP 2026004397A5 JP 2025161356 A JP2025161356 A JP 2025161356A JP 2025161356 A JP2025161356 A JP 2025161356A JP 2026004397 A5 JP2026004397 A5 JP 2026004397A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- polypeptide
- moiety
- agent
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934619P | 2014-01-31 | 2014-01-31 | |
| US61/934,619 | 2014-01-31 | ||
| US201461971009P | 2014-03-27 | 2014-03-27 | |
| US61/971,009 | 2014-03-27 | ||
| JP2016549123A JP6835586B2 (ja) | 2014-01-31 | 2015-01-30 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2021016630A JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A JP7819160B2 (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023134791A Division JP7819160B2 (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026004397A JP2026004397A (ja) | 2026-01-14 |
| JP2026004397A5 true JP2026004397A5 (enExample) | 2026-02-25 |
Family
ID=52484571
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549123A Active JP6835586B2 (ja) | 2014-01-31 | 2015-01-30 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2021016630A Active JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A Active JP7819160B2 (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2025161356A Pending JP2026004397A (ja) | 2014-01-31 | 2025-09-29 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549123A Active JP6835586B2 (ja) | 2014-01-31 | 2015-01-30 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2021016630A Active JP7337864B2 (ja) | 2014-01-31 | 2021-02-04 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
| JP2023134791A Active JP7819160B2 (ja) | 2014-01-31 | 2023-08-22 | マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9562073B2 (enExample) |
| EP (3) | EP4176896B1 (enExample) |
| JP (4) | JP6835586B2 (enExample) |
| KR (1) | KR102466591B1 (enExample) |
| CN (2) | CN114106099B (enExample) |
| AU (3) | AU2015210862B2 (enExample) |
| BR (1) | BR112016017649B1 (enExample) |
| DK (1) | DK3628328T3 (enExample) |
| ES (2) | ES3057033T3 (enExample) |
| IL (5) | IL294782B2 (enExample) |
| NZ (1) | NZ722401A (enExample) |
| RU (1) | RU2016135239A (enExample) |
| WO (1) | WO2015116933A2 (enExample) |
| ZA (1) | ZA202208159B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| CN105722859B (zh) * | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| NZ718283A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| US9562073B2 (en) | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| EP3296395B2 (en) | 2015-05-13 | 2024-06-19 | Chugai Seiyaku Kabushiki Kaisha | Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion |
| EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| CN106519037B (zh) * | 2015-09-11 | 2019-07-23 | 科济生物医药（上海）有限公司 | 可活化的嵌合受体 |
| FI3377103T4 (fi) | 2015-11-19 | 2025-04-16 | Revitope Limited | Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten |
| JP2019508036A (ja) | 2016-02-16 | 2019-03-28 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 免疫療法組成物及び方法 |
| BR112019008727A2 (pt) | 2016-11-28 | 2019-07-16 | Chugai Seiyaku Kabushiki Kaisha | domínio de ligação ao antígeno, e polipeptídeo incluindo seção de transporte |
| JP7626577B2 (ja) | 2016-11-28 | 2025-02-07 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| BR112019011564A2 (pt) | 2016-12-09 | 2019-10-22 | Seattle Genetics Inc | anticorpos bivalentes mascarados por hélices superenroladas |
| SG11201909160WA (en) | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| JP2020530554A (ja) * | 2017-07-20 | 2020-10-22 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用 |
| JP2020531430A (ja) * | 2017-08-16 | 2020-11-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 |
| EP3694885A1 (en) | 2017-10-14 | 2020-08-19 | CytomX Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| KR20200077534A (ko) * | 2017-10-20 | 2020-06-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 이종 단백질 생성을 위한 인공 분비 펩티드 |
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| JP7482630B2 (ja) * | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| KR20260046525A (ko) | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| US20210253672A1 (en) | 2018-05-30 | 2021-08-19 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule containing single domain antibody |
| JP7414736B2 (ja) | 2018-05-30 | 2024-01-16 | 中外製薬株式会社 | アグリカン結合ドメインおよび運搬部分を含むポリペプチド |
| EP3827019A1 (en) | 2018-07-24 | 2021-06-02 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3849611A4 (en) * | 2018-09-11 | 2022-06-15 | Georgia Tech Research Corporation | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY PROFILING |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| JP2022504802A (ja) | 2018-10-11 | 2022-01-13 | インヒブルクス インコーポレイテッド | ５ｔ４シングルドメイン抗体およびその治療組成物 |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| CA3123872A1 (en) | 2018-12-28 | 2020-07-02 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
| KR20220022112A (ko) | 2019-03-21 | 2022-02-24 | 이뮤노젠 아이엔씨 | 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법 |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
| JP2022535924A (ja) * | 2019-06-06 | 2022-08-10 | ジャナックス セラピューティクス，インク． | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| WO2020251878A1 (en) | 2019-06-11 | 2020-12-17 | Bristol-Myers Squibb Company | Anti-ctla4 antibody prodruggable (probody) at a cdr position |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| JP7789002B2 (ja) | 2020-01-29 | 2025-12-19 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物 |
| JP2023521384A (ja) | 2020-04-09 | 2023-05-24 | シートムエックス セラピューティクス，インコーポレイテッド | 活性化可能抗体を含む組成物 |
| WO2021207669A1 (en) * | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| EP4138998A4 (en) * | 2020-04-24 | 2024-05-22 | The Administrators of The Tulane Educational Fund | Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the ace2 receptor |
| CN116096754A (zh) | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| EP4631977A3 (en) | 2020-08-11 | 2025-12-10 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| WO2023034825A1 (en) | 2021-08-30 | 2023-03-09 | Cytomx Therapeutics, Inc. | Method for determining protease activity in a biological sample |
| IL311971A (en) | 2021-10-08 | 2024-06-01 | Cytomx Therapeutics Inc | Activatable cytokine constructs and related compositions and methods |
| TW202334185A (zh) | 2021-10-08 | 2023-09-01 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 可經活化之細胞介素構築體和組合方法 |
| WO2023064955A1 (en) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex |
| US20230174995A1 (en) | 2021-10-15 | 2023-06-08 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex |
| KR20240115809A (ko) | 2021-10-15 | 2024-07-26 | 싸이톰스 테라퓨틱스, 인크. | 활성화 가능한 폴리펩타이드 복합체 |
| US20250333539A1 (en) | 2022-03-23 | 2025-10-30 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| JP2025525880A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| JP2025525867A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| CN120112547A (zh) | 2022-11-16 | 2025-06-06 | 瑞泽恩制药公司 | 包含膜结合il-12和蛋白酶可裂解接头的嵌合蛋白 |
| EP4695281A1 (en) | 2023-04-12 | 2026-02-18 | CytomX Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120936384A (zh) | 2023-04-12 | 2025-11-11 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| EP0279862B1 (en) | 1986-08-28 | 1993-11-03 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| AR007087A1 (es) | 1996-05-10 | 1999-10-13 | Danisco | Una codificacion de fragmento de adn aislado para una enzima que posee actividad de alfa-glucuronidasa, fragmento de adn correspondiente, vectorrecombinante que tiene insertada dicha codificacion de fragmento de adn, celula huesped transformada con dicho vector recombinante, metodo para producir alfa- |
| AUPO930697A0 (en) | 1997-09-19 | 1997-10-09 | Walter And Eliza Hall Institute Of Medical Research, The | Catalytic antibodies and a method of producing same |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| ES2299244T3 (es) | 1998-05-13 | 2008-05-16 | Domantis Limited | Sistema de exposicion de fagos para la seleccion de proteinas correctamente plegadas. |
| WO2001055301A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| US20110131679A2 (en) | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| EP1286700A2 (en) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| AU2001280464A1 (en) * | 2000-08-04 | 2002-02-18 | Eli Lilly And Company | C1q-related factor, homologous polypeptides and therapeutic uses thereof |
| WO2002030460A2 (en) | 2000-10-09 | 2002-04-18 | Isis Innovation Ltd. | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU2002230630A1 (en) | 2000-11-08 | 2002-05-21 | Beth Israel Deaconess Medical Center, Inc. | Methods for determining protease cleavage site motifs |
| US20050208602A1 (en) | 2001-08-10 | 2005-09-22 | Rosen Craig A | 89 human secreted proteins |
| US7439319B2 (en) | 2001-09-14 | 2008-10-21 | Burnham Institute For Medical Research | Selective substrates for matrix metalloproteinases |
| WO2003038083A1 (en) * | 2001-10-29 | 2003-05-08 | Bayer Healthcare Ag | Regulation of human type i adenylate cyclase |
| CN101044154A (zh) | 2002-02-14 | 2007-09-26 | 威廉·J·鲁特 | 治疗宿主中切割的嵌合分子 |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| US9079936B2 (en) | 2003-07-01 | 2015-07-14 | University Of Maryland, Baltimore | Derivatives of APF and methods of use |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| CA2592249C (en) * | 2004-12-20 | 2014-07-29 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
| EP1865981A2 (en) * | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
| AU2006284651C1 (en) | 2005-08-31 | 2013-09-12 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
| JP5219819B2 (ja) * | 2005-10-21 | 2013-06-26 | カタリスト・バイオサイエンシーズ・インコーポレイテッド | 補体活性化を阻害する修飾プロテアーゼ |
| JP2009529522A (ja) | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| BRPI0717638A2 (pt) | 2006-10-27 | 2013-11-12 | Genentech Inc | Anticorpors e imunoconjugados e usos para os mesmos |
| US20090304719A1 (en) | 2007-08-22 | 2009-12-10 | Patrick Daugherty | Activatable binding polypeptides and methods of identification and use thereof |
| GB0819287D0 (en) | 2008-10-22 | 2008-11-26 | Univ Bradford | Compounds |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
| AU2010215761B2 (en) * | 2009-02-23 | 2017-04-06 | Cytomx Therapeutics, Inc | Proproteins and methods of use thereof |
| CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
| US20120157824A1 (en) | 2009-09-02 | 2012-06-21 | Nanoscale Corporation | Mri and optical assays for proteases |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US20110214205A1 (en) | 2010-02-26 | 2011-09-01 | Monsanto Technology Llc. | Isolated Novel Nucleic Acid and Protein Molecules from Foxtail Millet and Methods of Using Those Molecules to Generate Transgenic Plants with Enhanced Agronomic Traits |
| EP2650003B1 (en) * | 2010-05-20 | 2016-07-27 | Allergan, Inc. | Degradable clostridial toxins |
| WO2012158818A2 (en) | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| CA2836338C (en) * | 2011-05-16 | 2022-05-03 | Koninklijke Philips N.V. | Tetrazine derivatives used in bio-orthogonal drug activation |
| US20130078201A1 (en) | 2011-09-28 | 2013-03-28 | Susan Daly | Topical sunscreen compositions |
| CN110078827A (zh) * | 2012-04-27 | 2019-08-02 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| US9856314B2 (en) * | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| EP2863948B1 (en) * | 2012-06-22 | 2018-10-24 | Cytomx Therapeutics Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| WO2014107559A1 (en) | 2013-01-03 | 2014-07-10 | Branders.Com, Inc. | Methods and apparatus for determining a score value for criteria associated with a gift |
| CN105008918A (zh) | 2013-01-04 | 2015-10-28 | 西托姆克斯治疗公司 | 用于检测生物系统中的蛋白酶活性的组合物和方法 |
| EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS FOR SELECTIVE DRUG ADMINISTRATION AND METHOD OF USE |
| WO2014193973A2 (en) | 2013-05-28 | 2014-12-04 | Dcb-Usa Llc | Antibody locker for the inactivation of protein drug |
| NZ718283A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
| US9562073B2 (en) | 2014-01-31 | 2017-02-07 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CA2984892A1 (en) * | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
| BR112017023862A2 (pt) * | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| IL292798A (en) | 2015-05-04 | 2022-07-01 | Cytomx Therapeutics Inc | Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MY200695A (en) | 2016-11-03 | 2024-01-11 | Bristol Myers Squibb Co | Activatable anti-ctla-4 antibodies and uses thereof |
| WO2018165619A1 (en) | 2017-03-09 | 2018-09-13 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| CA3120327A1 (en) | 2018-12-06 | 2020-06-11 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof |
-
2015
- 2015-01-30 US US14/610,468 patent/US9562073B2/en active Active
- 2015-01-30 EP EP22195225.2A patent/EP4176896B1/en active Active
- 2015-01-30 JP JP2016549123A patent/JP6835586B2/ja active Active
- 2015-01-30 CN CN202111432527.8A patent/CN114106099B/zh active Active
- 2015-01-30 ES ES22195225T patent/ES3057033T3/es active Active
- 2015-01-30 AU AU2015210862A patent/AU2015210862B2/en active Active
- 2015-01-30 WO PCT/US2015/013776 patent/WO2015116933A2/en not_active Ceased
- 2015-01-30 ES ES19194203T patent/ES2932777T3/es active Active
- 2015-01-30 KR KR1020167023971A patent/KR102466591B1/ko active Active
- 2015-01-30 IL IL294782A patent/IL294782B2/en unknown
- 2015-01-30 RU RU2016135239A patent/RU2016135239A/ru not_active Application Discontinuation
- 2015-01-30 IL IL302642A patent/IL302642B2/en unknown
- 2015-01-30 NZ NZ722401A patent/NZ722401A/en unknown
- 2015-01-30 BR BR112016017649-9A patent/BR112016017649B1/pt active IP Right Grant
- 2015-01-30 EP EP15705429.7A patent/EP3099319A2/en not_active Withdrawn
- 2015-01-30 CN CN201580016781.6A patent/CN106459153B/zh active Active
- 2015-01-30 IL IL317045A patent/IL317045A/en unknown
- 2015-01-30 IL IL270562A patent/IL270562B/en unknown
- 2015-01-30 DK DK19194203.6T patent/DK3628328T3/da active
- 2015-01-30 EP EP19194203.6A patent/EP3628328B1/en active Active
-
2016
- 2016-07-27 IL IL246988A patent/IL246988A0/en unknown
- 2016-12-27 US US15/390,975 patent/US10138272B2/en active Active
-
2018
- 2018-10-15 US US16/160,846 patent/US11028126B2/en active Active
-
2020
- 2020-07-14 AU AU2020205249A patent/AU2020205249B2/en active Active
-
2021
- 2021-02-04 JP JP2021016630A patent/JP7337864B2/ja active Active
- 2021-04-26 US US17/240,278 patent/US11884746B2/en active Active
-
2022
- 2022-07-21 ZA ZA2022/08159A patent/ZA202208159B/en unknown
-
2023
- 2023-08-22 JP JP2023134791A patent/JP7819160B2/ja active Active
- 2023-12-07 AU AU2023278068A patent/AU2023278068A1/en active Pending
- 2023-12-08 US US18/534,263 patent/US20240150402A1/en active Pending
-
2025
- 2025-09-29 JP JP2025161356A patent/JP2026004397A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026004397A5 (enExample) | ||
| JP2022046569A5 (enExample) | ||
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| JP2022064924A5 (enExample) | ||
| JP2022065174A5 (enExample) | ||
| JP2017509594A5 (enExample) | ||
| JP2022512124A5 (enExample) | ||
| JP2018504925A5 (enExample) | ||
| Kipriyanov et al. | Single-chain antibody streptavidin fusions: tetrameric bifunctional scFv-complexes with biotin binding activity and enhanced affinity to antigen | |
| JP2021178823A5 (enExample) | ||
| JP2016521707A5 (enExample) | ||
| JP4549533B2 (ja) | マスト細胞の脱顆粒を阻害するためのハイブリッドタンパク質とその使用 | |
| CN120248140A (zh) | 基质金属蛋白酶可裂解的和丝氨酸或半胱氨酸蛋白酶可裂解的底物及其使用方法 | |
| TW202146456A (zh) | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 | |
| JP2018520092A5 (enExample) | ||
| JP2004523205A5 (enExample) | ||
| CN107043406B (zh) | 化合物、连接子-药物、及配体-药物耦合体 | |
| JP2018520991A5 (enExample) | ||
| HRP20220631T1 (hr) | Supstrati koje mogu cijepati matrične metaloproteaze i serinske proteaze, te postupci njihove uporabe | |
| JP2020537649A (ja) | 活性化可能抗ｃｄ７１抗体による薬物コンジュゲート及びこの使用の方法 | |
| RU2015156888A (ru) | Композиции и методы конъюгирования активируемых антител | |
| JP2017518748A5 (enExample) | ||
| CN102665768A (zh) | 肽清除剂 | |
| JPS63503144A (ja) | 葉酸類縁体のアミン誘導体 | |
| CN105579066A (zh) | 使用亲和性树脂合成adc的方法 |